Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-Current Deffered Revenue (2021 - 2025)

ARS Pharmaceuticals' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 26.24% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, down 26.24%, while the annual FY2025 figure was $1.1 million, 26.24% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $1.1 million at ARS Pharmaceuticals, down from $1.3 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $3.0 million in Q4 2021 and bottomed at $1.1 million in Q2 2025.
  • The 4-year median for Non-Current Deffered Revenue is $1.3 million (2025), against an average of $1.7 million.
  • The largest annual shift saw Non-Current Deffered Revenue dropped 4.74% in 2022 before it fell 26.24% in 2025.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $3.0 million in 2021, then fell by 4.74% to $2.9 million in 2022, then plummeted by 46.32% to $1.5 million in 2024, then fell by 26.24% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Non-Current Deffered Revenue are $1.1 million (Q4 2025), $1.3 million (Q3 2025), and $1.1 million (Q2 2025).